While the market anticipates a compound annual growth rate of 5.47% over the next seven years, the competitive landscape is shifting. Newer drug classes like GLP-1 receptor agonists and SGLT2 inhibitors are increasingly influencing clinical guidelines due to their weight-loss and cardiovascular benefits. Consequently, manufacturers of DPP-4 inhibitors are pivoting toward affordability and supply-chain efficiency to maintain their market position.

North America remains the dominant region, holding a 37.8% market share in 2025, buoyed by robust retail pharmacy infrastructure and established reimbursement pathways. Meanwhile, generic manufacturers—including Lupin, Sun Pharmaceutical, and Dr. Reddy's Laboratories—are playing a critical role in sustaining volume as branded patents expire. The industry's focus is moving away from premium pricing toward therapeutic utility, with fixed-dose combinations featuring metformin serving as a primary strategy to reduce pill burden for aging patient populations.